Avadel Pharmaceuticals PLC
NASDAQ:AVDL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.94
18.82
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Avadel Pharmaceuticals PLC
Operating Expenses
Avadel Pharmaceuticals PLC
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Operating Expenses
-$191m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-11%
|
||
Perrigo Company PLC
NYSE:PRGO
|
Operating Expenses
-$1.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
||
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Operating Expenses
-$2.9B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-14%
|
||
Cosmo Pharmaceuticals NV
SIX:COPN
|
Operating Expenses
-€53.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
||
Ovoca Bio PLC
LSE:OVB
|
Operating Expenses
-€4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
7%
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Operating Expenses?
Operating Expenses
-191m
USD
Based on the financial report for Sep 30, 2024, Avadel Pharmaceuticals PLC's Operating Expenses amounts to -191m USD.
What is Avadel Pharmaceuticals PLC's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-11%
Over the last year, the Operating Expenses growth was -32%. The average annual Operating Expenses growth rates for Avadel Pharmaceuticals PLC have been -36% over the past three years , -20% over the past five years , and -11% over the past ten years .